March 1, 2022
Life Sciences
  • The U.S. Patent and Trademark Office ruled that the Broad Institute of MIT and Harvard owns the rights to the genome editing technology CRISPR. The decision invalidates patent rights UC Berkeley granted gene-editing companies developing human therapies. It also means that biotech companies will now have to negotiate with the Broad Institute in order to use CRISPR to develop treatments. (Article here)